PROCUR Why Procur Has Been Prescribed for You

Total Page:16

File Type:pdf, Size:1020Kb

PROCUR Why Procur Has Been Prescribed for You Consumer Medicine Information Ask your doctor if you have any questions about PROCUR why Procur has been prescribed for you. Cyproterone acetate 50 mg and 100 mg tablets This medicine is available only with a doctor's prescription. What is in this leaflet Before you take Procur Please read this leaflet carefully before you start taking Procur When you must not take it This leaflet answers some common questions about Procur. It does not contain all the available Do not take Procur if you have an allergy to: information. It does not take the place of talking • any medicine containing cyproterone acetate to your doctor or pharmacist. • any of the ingredients listed at the end of this leaflet All medicines have risks and benefits. Your doctor has weighed the risks of you taking Procur against Some of the symptoms of an allergic reaction may the benefits they expect it will have for you. include: • difficulty in breathing or wheezing If you have any concerns about taking this • shortness of breath medicine, ask your doctor or pharmacist. • swelling of the face, tongue, lips, or other parts of the body Keep this leaflet with the medicine. You may • hives on the skin, rash, or itching need to read it again. Do not take Procur if: What Procur is used for • you are allergic to cyproterone acetate or any other ingredient listed at the end of this leaflet Procur tablets contain the active ingredient • you are pregnant cyproterone acetate. Cyproterone acetate is an • you are breastfeeding antiandrogen. It works by blocking the actions of • you suffer from liver diseases (including sex hormones (androgens) that are produced previous or existing liver tumours, Dubin- mainly in men but also, to a lesser extent in Johnson syndrome or Rotor syndrome) women. • you have a history of jaundice (yellowing of skin and/or eyes) or persistent itching during a In men, Procur is used: previous pregnancy • to treat prostate cancer • you have a history of herpes in pregnancy • to control sexual desire in men who have an • you suffer from severe depression which you increased sex drive (hypersexuality) and/or have had for many months sexual abnormalities. • you have previous or existing blood clots (thrombosis or embolism) • In women, Procur is used: you have abnormal red blood cells (sickle-cell anaemia) • to treat severe signs of androgenisation such • You have severe diabetes that affects your as excessive hair growth. blood circulation 1 • you have previous or existing benign brain It is known that cyproterone acetate passes tumour (meningioma) into breastmilk). Your doctor can discuss with • you have wasting disease (a disease causing you the risks and benefits involved. muscle loss or loss of strength, with the If you have not told your doctor about any of the exception of prostate cancer) above, tell them before you start taking Procur. Procur contains lactose monohydrate. If you have Taking other medicines been told by your doctor that you have an intolerance to some sugars, contact your doctor Tell your doctor if you are taking any other before taking Procur. medicines, including medicines that you buy without a prescription from your pharmacy, If you are a male your doctor may instruct you to supermarket or health food shop. You should have a sperm count recorded before starting also tell any health professional who is treatment. There may be a reduction in the overall prescribing a new medication for you that you are number of sperm during the treatment but it will taking Procur. gradually recover after you have stopped the treatment. The long-term effects on female Some medicines may interfere with Procur. These fertility are not known include: • medicines used to treat diabetes Do not take it after the expiry date (EXP) printed • medicines used to treat fungal infections, on the back. If you take it after the expiry date has including ketoconazole, itraconzole, passed, it may not work as well. clotrimazole • ritonavir, a medicine used in the treatment of Do not take it if the packaging is torn or shows HIV infections signs of tampering. • phenytoin, a medicine used to treat epilepsy • If you are not sure whether you should start rifampicin taking Procur, talk to your doctor. • St John’s wort, a herbal remedy • Statins, medicines used to lower cholesterol levels Before you start to take it These medicines may be affected by Procur, or Tell your doctor if: may affect how well it works. You may need different amounts of your medicine, or you may 1. you suffer from liver disease, previous or need to take different medicines. existing liver tumours, previous or existing benign brain tumours, diabetes, shortness of Your doctor or pharmacist has more information breath, history of blood clotting, sickle cell on medicines to be careful with or avoid while anaemia or anaemia. taking Procur. 2. you have allergies to: • any other medicines How to take Procur • any other substances, such as foods, preservatives or dyes. How much to take 3. you are pregnant or intend to become pregnant. Follow all directions given to you by your doctor or pharmacist carefully. Your doctor may have 4. you are breastfeeding or planning to prescribed a different dose. breastfeed. Men: Swallow the tablets whole with some liquids Prostate Cancer after meals. The usual total daily dose is 100-300 mg of Procur in divided doses. Your doctor may request you to When to take it take Procur with other medicines and/or change your dose during treatment. Take your medicine after a meal, at about the same time each day. Control sexual desire Taking your tablets at the same time each day will The usual dose is 50 mg of Procur twice daily and have the best effect. It will also help you may be increased. Once the desired effect is remember when to take the tablets. achieved, your dose may be gradually lowered. Women: How long to take it Childbearing age Continue taking your medicine for as long as If you are pregnant, do not take Procur. your doctor tells you. Therefore, pregnancy must be excluded before This medicine helps you control your condition but starting treatment. does not cure it. Therefore, you must take it every day. The usual dose is 50 mg of Procur taken once daily for 10 days per month. This dose may be If you forget to take it increased in severe symptoms. If you are of a childbearing age you should Do not take a double dose to make up for the commence your tablet on the 1st day of the cycle dose that you missed. (= 1st day of bleeding). If you have no menstrual Missed Procur tablets may diminish the periods, your treatment can commence effectiveness of the treatment and may lead to immediately. In this case, the first day of breakthrough bleeding in women. treatment is to be regarded as the 1st day of the cycle. If you are also taking oral contraceptive and more than 12 hours elapsed from the time Procur was Additionally, your doctor will advise the most due to be taken, note that contraceptive appropriate contraceptive for you to take to protection in this cycle may be reduced. If bleeding provide the necessary contraceptive protection fails to occur after this cycle, there is a risk of and to stabilise your cycle. pregnancy. Your doctor may need to check whether you are pregnant before you can The length of use depends on the severity of your continue treatment. symptoms and the extent of response to treatment. Your doctor should re-evaluate the While you are taking Procur treatment periodically as long-term use should be avoided. Things you must do Postmenopausal or have had a hysterectomy If you are postmenopausal or have had a If you are about to be started on any new hysterectomy, Procur maybe administrated alone. medicine tell your doctor and pharmacist that The average dose is 25-50 mg of Procur once daily you are taking Procur. for 21 days, followed by a 7-day tablet-free interval. If you become pregnant while taking this medicine, tell your doctor immediately. How to take it If you are about to have any blood tests, tell your doctor that you are taking this medicine. It may interfere with the results of some tests. Procur from working as well as it should in reducing abnormal sex drive. If you feel shortness of breath, tell you doctor. Shortness of breath has been reported in patients taking this medicine at high doses. In case of overdose Keep all of your doctor’s appointments so that If you take too much (overdose) your progress can be checked. Your doctor may do some tests from time to time Immediately telephone your doctor or the to make sure the medicine is working and to National Poisons Centre (telephone 0800 POISON prevent unwanted side effects. or 0800 764 766) or go to accident and emergency at your nearest hospital, if you think that you or Your doctor will check your liver function during anyone else may have taken too much Procur. treatment with Procur and whenever any symptoms or signs suggesting liver problems are Do this even if there are no signs of discomfort or observed. poisoning. You may need urgent medical attention. If you have diabetes, your doctor will monitor you to ensure that you receive the appropriate dose of oral antidiabetic or insulin whilst taking Procur. Side effects Your doctor will also check you red-blood cell Tell your doctor or pharmacist as soon as possible count to ensure you do not become anaemic if you do not feel well while you are taking during treatment with Procur.
Recommended publications
  • RIFAMPICIN Productinformation Sigma Prod
    RIFAMPICIN ProductInformation Sigma Prod. No. R3501 CH3 CH3 CAS NUMBER: 13292-46-1 HO SYNONYMS: Tubocin; Sinerdol; Rimactan; L-5103; Dione-21 Acetate; Archidyn; Arficin; 3-(4- CH3 O O OH O Methylpiperazinyliminomethyl)-rifamycin SV; NSC 113926; C OH OH CH 1 2 3 H C Rifampin ; Rifaldazine; Rifamycin AMP H3C 3 O NH H3C PHYSICAL PROPERTIES: CH3 N CH N Appearance: Orange-brown to red-brown powder.3 O OH N Molecular formula: C43H58N4O12 O Molecular weight: 823.0 O CH3 CH3 EmM (max absorbance, phosphate buffer, pH 7.38): 33.20 (237 nm); 32.10 (255 nm); 27.00 (334 nm); 15.40 (475 nm)2,4 pKa (in water):1.7 (4-hydroxyl group), 7.9 (4-piperazine nitrogen); in methylcellosolve-water (4:1): 3.6 (4- hydroxyl group), 6.7 (3-piperazine nitrogen)4 pI (in water): 4.84 25° 4 Optical rotation: [α]D =+10.6° (c=0.5% in CDCl3) Melting point: 183-188°C (dec.)2,4 METHOD OF PREPARATION: Methods of preparation have been reported.4,5 The NMR, UV, IR, Mass spectra, Thin-Layer chromatography and HPLC methods of detection have been reported.4,5,6 A colorimetric test for identification was reported.4 STABILITY / STORAGE: Rifampicin (Rif) should be stable for at least two years when stored desiccated at -20°C and protected from light.3 Rif is stable as a solid at temperatures up to 70EC.4 SOLUBILITY / SOLUTION STABILITY: Rif is soluble in dimethylsulfoxide (~100mg/mL), dimethylformamide, methanol (16 mg/ml, 25EC), chloroform (349 mg/ml, 25°C), ethyl acetate (108 mg/ml, 25°C), and acetone (14 mg/ml, 25°C).4,6,7,8,9 Rif is slightly soluble in water at 25°C: 2.5 mg/ml, pH 7.3; 1.3 mg/ml, pH 4.3; and in 95% ethanol (∼10 mg/mL).4 Rif is soluble at 37°C: in 0.1 N HCl, 200 mg/ml and in phosphate buffer pH 7.4, 9.9 mg/ml.4 R3501 Page 1 of 4 03/28/97 - ARO RIFAMPICIN Sigma Prod.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • Ketoconazole (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Ketoconazole (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada APO-Ketoconazole; Ketoconazole-200; TEVA-Ketoconazole Warning This drug is not for use to treat certain types of fungal infections. This includes fungal infections of the skin, nails, or brain. Talk with the doctor. This drug must only be used when other drugs cannot be used or have not worked. Talk with your doctor to be sure that the benefits of this drug are more than the risks. Very bad and sometimes deadly liver problems like the need for a liver transplant have happened with this drug. Some people did not have a raised chance of liver problems before taking this drug. Most of the time, but not always, liver problems have gone back to normal after this drug was stopped. Call your doctor right away if you have signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes. Blood tests will be needed to watch for any liver problems. Talk with your doctor. Taking this drug with certain other drugs may raise the chance of very bad and sometimes deadly heart problems like a heartbeat that is not normal. Do not take this drug if you are taking any of these drugs: Cisapride, disopyramide, dofetilide, dronedarone, methadone, pimozide, quinidine, or ranolazine. Ketoconazole (Systemic) 1/6 What is this drug used for? It is used to treat fungal infections.
    [Show full text]
  • Treatment of Peripheral Precocious Puberty
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks Treatment of Peripheral Precocious Puberty Melissa Schoelwer, MD and Erica A Eugster, MD Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana Send correspondence to: 705 Riley Hospital Drive, Room 5960 Indianapolis, IN 46202 Phone: 317-944-3889 Fax: 317-944-3882 Email: [email protected] __________________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schoelwer, M., & Eugster, E. A. (2016). Treatment of Peripheral Precocious Puberty. In Puberty from Bench to Clinic (Vol. 29, pp. 230-239). Karger Publishers. http://dx.doi.org/10.1159/000438895 Peripheral Precocious Puberty Abstract There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and Familial Male-Limited Precocious Puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.
    [Show full text]
  • CYP3A4 Mediated Pharmacokinetics Drug Interaction Potential of Maha
    www.nature.com/scientificreports OPEN CYP3A4 mediated pharmacokinetics drug interaction potential of Maha‑Yogaraj Gugglu and E, Z guggulsterone Sarvesh Sabarathinam1, Satish Kumar Rajappan Chandra2 & Vijayakumar Thangavel Mahalingam1* Maha yogaraja guggulu (MYG) is a classical herbomineral polyherbal formulation being widely used since centuries. The aim of this study was to investigate the efect of MYG formulation and its major constituents E & Z guggulsterone on CYP3A4 mediated metabolism. In vitro inhibition of MYG and Guggulsterone isomers on CYP3A4 was evaluated by high throughput fuorometric assay. Eighteen Adult male Sprague–Dawley rats (200 ± 25 g body weight) were randomly divided into three groups. Group A, Group B and Group C were treated with placebo, MYG and Standard E & Z guggulsterone for 14 days respectively by oral route. On 15th day, midazolam (5 mg/kg) was administered orally to all rats in each group. Blood samples (0.3 mL) were collected from the retro orbital vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 12 and 24 h of each rat were collected. The fndings from the in vitro & in vivo study proposed that the MYG tablets and its guggulsterone isomers have drug interaction potential when consumed along with conventional drugs which are CYP3A4 substrates. In vivo pharmacokinetic drug interaction study of midazolam pointed out that the MYG tablets and guggulsterone isomers showed an inhibitory activity towards CYP3A4 which may have leads to clinically signifcant interactions. Te use of alternative medicine such as herbal medicines, phytonutrients, ayurvedic products and nutraceuticals used widely by the majority of the patients for their primary healthcare needs.
    [Show full text]
  • Studies on the Interactions Between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol
    1844 Biol. Pharm. Bull. 27(11) 1844—1849 (2004) Vol. 27, No. 11 Studies on the Interactions between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol a b,1) b b, c Takashi SATOH, Yuki TOMIKAWA, Kaori TAKANASHI, Shinji ITOH, * Shungo ITOH, and b Itsuo YOSHIZAWA a Yakuhan Pharmaceutical Co., Ltd.; Kitahiroshima, Hokkaido 061–1111, Japan: b Hokkaido College of Pharmacy; Otaru, Hokkaido 047–0264, Japan: and c Japan Seamen-Relief-Association Otaru Hospital; 1–7–10 Ironai, Otaru, Hokkaido 047–0031, Japan. Received July 5, 2004; accepted August 27, 2004 To determine the inhibition effects of drugs on the glucuronidation of estradiol (E2), 29 drugs that have been reported to induce gynecomastia were examined in the presence of UDP-glucuronic acid using human hepatic microsomes (pooled) as the enzyme source. The percentage inhibition of the E2 glucuronidation was determined at drug concentrations of 1 mM (approximate therapeutic concentration) and 100 mM (non-clinical overdose con- centration) based on the rate constants for the 3- and 17-glucuronidation of E2 (11.2 and 2.52 pmol/min/mg pro- tein, respectively). The only drug that exhibited 50% or higher inhibition of the 3-glucuronidation at a concen- tration of 1 mM was manidipine (54.4%). When the concentration was 100 mM, manidipine exhibited 100% inhibi- tion of the 3-glucuronidation, and other drugs that exhibited 50% or higher inhibition of the 3-glucuronidation were nicardipine (92%), nisoldipine (90%), nifedipine (84%), domperidone (81%), tacrolimus (80%), nitrendip- ine (77%) and ketoconazole (69%).
    [Show full text]
  • Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?
    pharmaceutics Review Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication? Luíse L. Chaves 1,2,*, Yuri Patriota 2, José L. Soares-Sobrinho 2 , Alexandre C. C. Vieira 1,3, Sofia A. Costa Lima 1,4 and Salette Reis 1,* 1 Laboratório Associado para a Química Verde, Rede de Química e Tecnologia, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal; [email protected] (A.C.C.V.); slima@ff.up.pt (S.A.C.L.) 2 Núcleo de Controle de Qualidade de Medicamentos e Correlatos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil; [email protected] (Y.P.); [email protected] (J.L.S.-S.) 3 Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil 4 Cooperativa de Ensino Superior Politécnico e Universitário, Instituto Universitário de Ciências da Saúde, 4585-116 Gandra, Portugal * Correspondence: [email protected] (L.L.C.); shreis@ff.up.pt (S.R.) Received: 30 October 2020; Accepted: 4 December 2020; Published: 11 December 2020 Abstract: Leprosy disease remains an important public health issue as it is still endemic in several countries. Mycobacterium leprae, the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
    [Show full text]
  • Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control and Prevention Office of Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination June 2013 This document is accessible online at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Suggested citation: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Table of Contents Introduction 1 Methodology for Preparation of these Guidelines 2 The Role of Rifamycins in Tuberculosis Treatment 4 Managing Drug Interactions with Antivirals and Rifampin 5 Managing Drug Interactions with Antivirals and Rifabutin 9 Treatment of Latent TB Infection with Rifampin or Rifapentine 10 Treating Pregnant Women with Tuberculosis and HIV Co-infection 10 Treating Children with HIV-associated Tuberculosis 12 Co-treatment of Multidrug-resistant Tuberculosis and HIV 14 Limitations of these Guidelines 14 HIV-TB Drug Interaction Guideline Development Group 15 References 17 Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults 21 Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children 22 Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults 23 Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children 25 Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults 26 ii Introduction Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV infection.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • KETOCONAZOLE Your Dosage Is: Ketoconazole Can Increase Liver Enzymes
    Your dosage is: KETOCONAZOLE Ketoconazole can increase liver enzymes . 200 mg tablet This usually does not give any symptoms. Other names: Nizoral Rarely, hepatitis (an inflammation of the ____tablet(s) (____mg) ____time(s) a day liver) can occur. Signs of this are yellowing WHY is this drug prescribed? of the eyes and skin, dark urine, fever, or nausea and / or vomiting, pale stools, Ketoconazole is an antifungal drug. It is fatigue, and abdominal pain. Call your used to treat fungal infections in the mouth 20 mg / mL oral suspension doctor or pharmacist if these symptoms (like thrush), the esophagus, the genital occur. tract (like a yeast infection) and other areas. ____mL (____mg) ____ time(s) a day The drug may also be used to prevent a Other rare adverse effects that may occur relapse after treatment of the initial infection. Shake well before each use include lowering of white blood cells (cells that fight infections), and lowering of HOW should this drug be taken? Take ketoconazole for the duration of time it platelets (needed to help your blood clot). is prescribed. If you stop it earlier, your Inform your doctor if you notice any Ketoconazole is available in 200 mg tablets infection may come back. If the infection symptoms of fever, chills, bleeding or and a 20 mg/mL oral suspension. worsens or persists, consult your doctor. bruising. The dose of ketoconazole will depend on the What should you do if you FORGET a Your doctor will do regular blood tests to type of infection that is being treated. It is dose? verify your liver and adrenal gland function usually given once daily.
    [Show full text]
  • What's the Best Treatment for Cradle Cap?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ryan C. Sheffield, MD, Paul Crawford, MD What’s the best treatment Eglin Air Force Base Family Medicine Residency, Eglin Air for cradle cap? Force Base, Fla Sarah Towner Wright, MLS University of North Carolina at Chapel Hill Evidence-based answer Ketoconazole (Nizoral) shampoo appears corticosteroids to severe cases because to be a safe and efficacious treatment of possible systemic absorption (SOR: C). for infants with cradle cap (strength of Overnight application of emollients followed recommendation [SOR]: C, consensus, by gentle brushing and washing with usual practice, opinion, disease-oriented baby shampoo helps to remove the scale evidence, and case series). Limit topical associated with cradle cap (SOR: C). ® Dowden Health Media Clinical commentary ICopyrightf parents can’t leave it be, recommend brush to loosen the scale. Although mineral oil andFor a brush personal to loosen scale use noonly evidence supports this, it seems safe Cradle cap is distressing to parents. They and is somewhat effective. want everyone else to see how gorgeous This review makes me feel more FAST TRACK their new baby is, and cradle cap can make comfortable with recommending ketocon- their beautiful little one look scruffy. My azole shampoo when mineral oil proves If parents need standard therapy has been to stress to the insufficient. For resistant cases, a cute hat to do something, parents that it isn’t a problem for the baby. can work wonders. If the parents still want to do something
    [Show full text]